ArticleTranslational lung cancer research2025
Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT) followed by durvalumab. There are no reliable biomarkers predicting the response to this treatment. We aimed to analyze the relationship between soluble immune mediators and treatment response and to identify biomarkers predicting the treatment response in patients with unresectable stage III NSCLC. Methods: We prospectively enrolled 48 patients diagnosed with stage III NSCLC who underwent thoracic radiotherapy (cohort A). Of these patients, 29 received durvalumab after CCRT (cohort B). Peripheral blood samples were collected before radiotherapy and 6 weeks after durvalumab treatment. To identify soluble immune mediators associated with progression-free survival (PFS) and overall survival (OS), we examined the levels of 83 soluble immune mediators using a bead-based multiplex assay and calculated the concordance index (C-index). Results: At baseline, the high matrix metalloproteinase (MMP)-2 group exhibited the longest PFS and OS in cohort A (C-index: 0.70 and 0.75, respectively), whereas the high IFN-γ group had the worst PFS and OS in cohort B (C-index: 0.75 and 0.71, respectively). Furthermore, patients with greater increases in CXCL9, CXCL10, and CCL23 levels after durvalumab treatment had poor PFS and OS in cohort B (C-index >0.70). Conclusions: Our results suggest that PFS and OS are negatively affected by elevated CXCL9, CXCL10, and CCL23 levels after CCRT followed by durvalumab treatment. These soluble mediators may be useful tools for the clinical management of locally advanced NSCLC treated with PD-L1 therapy after CCRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.